Related Experiment Video

Updated: Jun 28, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients

Vasilios G Athyros1, Anna I Kakafika, Athanasios A Papageorgiou

  • 1Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki 546 42, Greece.

The Open Cardiovascular Medicine Journal
|October 25, 2008
PubMed

Insights

Statin therapy improved kidney function in heart disease patients. The increase in high-density lipoprotein cholesterol (HDL-C) due to statins independently boosted kidney function, suggesting broader lipid benefits.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Limited understanding of statin-induced HDL-C increase impact on renal function in coronary heart disease (CHD) patients.
  • Assessing the renal benefits of elevated HDL-C beyond LDL-C reduction is crucial.

Purpose of the Study:

  • To investigate the effect of statin-induced HDL-C increase on renal function in CHD patients.
  • To determine if HDL-C elevation independently contributes to renal function improvement.

Main Methods:

  • Post hoc analysis of the GREACE Study involving 1600 CHD patients.
  • Comparison between 880 patients on statins (primarily atorvastatin) and 720 not on statins over 3 years.
  • Analysis of lipid profiles and estimated glomerular filtration rate (eGFR) changes.

Main Results:

  • Statin-untreated group showed a 5.1% decrease in eGFR; statin-treated group showed a 9.8% increase in eGFR.
  • A 7% increase in HDL-C in the statin group was associated with a 5.6% increase in eGFR.
  • Each 5% rise in HDL-C correlated with a 1.78 odds ratio for eGFR increase.

Conclusions:

  • Statin treatment significantly enhances renal function in CHD patients.
  • Statin-induced HDL-C increase is an independent contributor to renal function improvement.
  • Improving HDL-C levels offers renal protective benefits in addition to LDL-C reduction.
Abstract

Keywords:
Renal functionand coronary heart diseasechronic kidney diseasedyslipidaemiahigh density lipoproteinstatins

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...